Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

(2017) Suzanne George et al.   IMMUNITY

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

(2017) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo

(2016) Zhang Zhang et al.   CANCER LETTERS

Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity

(2016) Myrella Vlenterie et al.   EUROPEAN JOURNAL OF CANCER

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

(2015) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

(2015) Akira Kawai et al.   LANCET ONCOLOGY

miR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α

(2015) CHUNYAN LI et al.   Molecular Medicine Reports

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

Activity of sunitinib in extraskeletal myxoid chondrosarcoma

(2014) S. Stacchiotti et al.   EUROPEAN JOURNAL OF CANCER

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Immunotherapy for solid tumors—a review for surgeons

(2013) Abdul Saied et al.   JOURNAL OF SURGICAL RESEARCH

WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition

(2013) Vickie Y. Jo et al.   PATHOLOGY

Sunitinib malate in solitary fibrous tumor (SFT)

(2012) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma

(2009) Alexander J. Chou et al.   CANCER

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

(2009) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

PDGF, TGF- , and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages

(2008) F. Ng et al.   BLOOD

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY